The two U.S. FDA approved oligonucleotide-based drugs on the market both have a modified chemical backbone made of phosphorothioates. The therapeutic advantages of the phosphorothioate group and the new types of gene expression-regulation oligonucleotide drugs that it is enabling are detailed in a Review article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website until December 13, 2014.
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...